文献速递头颈部肿瘤放疗放疗物理与技术

口咽癌自适应剂量递增放疗:一项治疗计划可行性研究

Adaptive dose escalated radiotherapy in oropharyngeal cancers: a treatment planning feasibility study.
PubMed 文献 · Radiat Oncol · 2022-02-05

本研究对20例放疗后复发的局部晚期口咽鳞癌患者进行回顾性再计划,利用Eclipse TPS v15.5、RapidPlan™和多准则优化,将GTV剂量分别递增至73 Gy和82 Gy,同时保持PTV65-GTV、PTV54和危及器官剂量在临床可接受范围。结果显示剂量递增未显著增加周围靶区及危及器官剂量,提示该自适应剂量递增方法可行,可开展介入性临床试验。

要点

  • 对20例放疗后复发的口咽鳞癌患者进行回顾性再计划,评估GTV剂量递增至73 Gy和82 Gy的可行性。
  • GTV剂量分别递增12.3%和26.2%,PTV54和危及器官剂量未受显著影响,接收>84 Gy的GTV体积远小于1.75 cc。
  • 结果提示该自适应剂量递增方法可行,可开展介入性临床试验。

核心结论

  • 该计划可行性研究显示,RapidPlan™联合多准则优化可将GTV剂量递增而不显著增加PTV65-GTV、PTV54或危及器官剂量,提示采用该方法的介入性临床试验可行。

研究设计与样本

  • 对20例已知放疗后复发的预后不良局部晚期口咽鳞癌患者,使用Eclipse TPS v15.5、RapidPlan™和多准则优化进行回顾性再计划。
  • 本中心PTV65给予65 Gy/30次,PTV54同步给予54 Gy/30次。
  • 原临床计划再优化作为对照组(I组),将计划拆分为两个15次计划,后15次用于将GTV剂量递增至73 Gy(II组)和82 Gy(III组),并创建30次总计划总和以记录计划评估参数和计划可交付性评估。

主要发现

  • 所有组PTV的D98%和D50%剂量覆盖相当,PTV65-GTV的D2%剂量水平增加。
  • 所有与PTV54相关的剂量水平基本未受剂量递增方案影响。
  • PTV65和PTVAll(PTV65加PTV54)的适形指数显示三组靶区覆盖相当。
  • 尽管II组和III组GTV剂量分别递增12.3%和26.2%,接收>84 Gy的GTV体积远小于1.75 cc。
  • 剂量递增组危及器官剂量增加,但增加无临床显著性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: A significant proportion of patients with poor prognosis squamous cell cancer of the oropharynx relapse loco-regionally despite radical (chemo)radiotherapy. If a predictive biomarker for disease control can be identified during treatment then individualised and adaptive treatment strategies may be employed. The aim of this study is to assess the feasibility of adaptive and dose-escalated RT to the gross tumour volume without increasing surrounding planning target volume doses and maintaining clinically acceptable organs at risk doses. MATERIALS AND METHODS: Twenty representative patients with poor prognosis locally advanced OPSCC who were known to have relapsed post RT, were re-planned retrospectively using Eclipse TPS v15.5, RapidPlan™ and multi-criteria optimisation. In our centre, PTV65 is treated with 65 Gy in 30 fractions while areas at risk of containing microscopic disease (PTV54) are treated synchronously to 54 Gy in 30 fractions. The original clinical plans were re-optimised to act as controls (Group I). These plans were split into two plans of 15 fractions each, with the latter 15 fractions used to escalate the dose to the GTV to 73 Gy (Group II) and 82 Gy (Group III). Plan sums were created for the total 30 fractions to record plan evaluation parameters along with assessments of plan deliverability. RESULTS: For all groups, the dose coverage at D98% and D50% for the PTVs were comparable. The D2% dose levels for PTV65-GTV increased. All dose levels associated with PTV54 remained largely unaffected by the dose escalation regimens. Conformity indices for PTV65 and PTVAll (PTV65 plus PTV54) reveal comparable target volume coverage across all three groups. Despite the GTV being escalated by 12.3% and 26.2% in groups II and III, the volume of GTV receiving > 84 Gy was considerably less than 1.75 cc. While OAR doses increased for the escalated groups, these increases were not clinically significant. CONCLUSION: This planning feasibility study exploring RapidPlan™ combined with multi-criteria optimisation has demonstrated that doses to the GTV may be escalated without increasing PTV65-GTV, PTV54 or OAR doses considerably, suggesting an interventional clinical trial using this approach would be feasible.

来源:Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Grocutt L, Paterson C, Valentine RM, et al. Adaptive dose escalated radiotherapy in oropharyngeal cancers: a treatment planning feasibility study. Radiat Oncol. 2022. PMID: 35123516. doi:10.1186/s13014-022-01991-x

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。